Q3 2025 Guardant Health Inc Earnings Call Transcript
Key Points
- Guardant Health Inc (GH) reported a 39% year-over-year revenue growth, reaching $265 million in Q3 2025.
- The company achieved a significant milestone by surpassing $1 billion in annualized revenue for the first time.
- Guardant360 Liquid, Tissue, and Reveal volumes experienced strong year-over-year growth, contributing to the company's success.
- The biopharma business saw an 18% revenue increase, with two additional companion diagnostic approvals in Q3.
- Shield testing revenue reached $24 million in Q3, driven by approximately 24,000 tests, showcasing strong demand and high adherence rates.
- Despite strong performance, Guardant Health Inc (GH) continues to face challenges in achieving commercial reimbursement for Shield tests, particularly from commercial payers.
- The company is still in the early stages of establishing reimbursement rates for commercial patients, which could impact future ASPs.
- There is uncertainty regarding the timeline for FDA approval and guideline inclusion for Shield Multi-Cancer Detection (MCD), which could affect future growth.
- Guardant Health Inc (GH) is investing heavily in expanding its commercial infrastructure, leading to increased operating expenses.
- The company reported an adjusted EBITDA loss of $45.5 million, indicating ongoing financial challenges despite revenue growth.
Good afternoon. Thank you for attending the Guardant Health Inc Q3 2025 earnings call. My name is Cameron, and I'll be your moderator for today. (Operator Instructions)
And I would now like to pass the conference over to your host, Zarak Khurshid with Guardant Health. You may proceed.
Thank you. Earlier today, Garden Health released financial results for the quarter ended September 30, 2025. Joining me today from Guardant are Helmi Eltoukhy, co-CEO; Amirali Talasaz, co-CEO; and Mike Bell, Chief Financial Officer.
Before we begin, I'd like to remind you that during this call, management will make forward-looking statements within the meaning of federal. Securities laws. These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated. This call will also include a discussion of non-GAAP financial measures which are adjusted to exclude certain specified items, additional
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
